Latest data from January 14, 2022
Number of Health Center respondents = 10 (83% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 25,493 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 36.75% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 6,905 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 43.60% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 61.06% | 53.87% |
| White, Hispanic/Latino Patients | 5.66% | 7.24% |
| Black/African American, Non-Hispanic/Latino Patients | 24.82% | 27.62% |
| Black/African American, Hispanic/Latino Patients | 0.16% | 0.20% |
| Asian Patients3 | 0.66% | 0.65% |
| American Indian/Alaska Native Patients3 | 0.18% | 0.10% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.96% | 1.43% |
| Patients with More Than One Race3 | 0.98% | 1.17% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.06% | 3.23% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.44% | 0.51% |
| Unreported/Refused to Report Race and Ethnicity | 3.02% | 3.97% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 1,075 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 76.82% |
| COVID-19 Immunization Series Completed | 545 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 65.64% |
| COVID-19 Immunization Series Additional | 1,533 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 58.38% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 21.95% | 32.66% | 40.51% |
| White, Hispanic/Latino Patients | 25.40% | 20.00% | 9.13% |
| Black/African American, Non-Hispanic/Latino Patients | 27.81% | 25.87% | 41.55% |
| Black/African American, Hispanic/Latino Patients | 0.09% | 0.00% | 0.13% |
| Asian Patients3 | 0.65% | 0.55% | 0.46% |
| American Indian/Alaska Native Patients3 | 0.19% | 0.37% | 0.59% |
| Native Hawaiian/Other Pacific Islander Patients3 | 2.70% | 2.20% | 0.20% |
| Patients with More Than One Race3 | 0.47% | 0.92% | 0.78% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 15.44% | 12.48% | 3.98% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 1.77% | 2.20% | 0.65% |
| Unreported/Refused to Report Race and Ethnicity | 3.53% | 2.75% | 2.02% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 0.00% |
| 1 to 24 Hours | 10.00% |
| More Than 24 Hours | 90.00% |
| N/A | 0.00% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 0.00% |
| Staffing to administer the vaccine | 40.00% |
| Vaccine confidence | 40.00% |
| Vaccine storage capacity | 0.00% |
| Vaccine supply | 10.00% |
| Other | 10.00% |
| None | 30.00% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 70.00% |
| Average Percent of Health Center Visits Conducted Virtually | 15.50% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 50.00% |
| Number of Mobile Van Sites | 5 |
| Number of Pop-up Clinics | 9 |
| Number of School-Based Vaccination Sites | 2 |
| Number of Family Vaccination Clinics | 3 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 70.00% |
| Refer patients to another organization that provides monoclonal antibody therapies | 40.00% |
| None | 10.00% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 0.00% |
| Patient awareness/education | 0.00% |
| Staffing capacity | 10.00% |
| Therapy administration/onsite logistics | 10.00% |
| Other | 0.00% |
| None | 90.00% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 3 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 14,670 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provide to Existing Health Center Patients | 66.67% |
| Provide to General Public Who Came to the Health Center | 100.00% |
| Provide at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 0.00% |
| Provide at Other Community Events | 66.67% |
| Provide through direct outreach to specific populations (i.e., individuals experiencing homelessness, MSAWs, residents of public housing, individuals with limited English proficiency) | 0.00% |
| Other | 0.00% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 0 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication5 | - |
Oral Antiviral Medication Distribution by Race and Ethnicity5
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | - |
| White, Hispanic/Latino Patients | - |
| Black/African American, Non-Hispanic/Latino Patients | - |
| Black/African American, Hispanic/Latino Patients | - |
| Asian Patients3 | - |
| American Indian/Alaska Native Patients3 | - |
| Native Hawaiian/Other Pacific Islander Patients3 | - |
| Patients with More Than One Race3 | - |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | - |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | - |
| Unreported/Refused to Report Race and Ethnicity | - |
Oral Antiviral Medication Distribution by Special/Vulnerable Population5
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | - |
| Patients Experiencing Homelessness | - |
| Patients Who Are Residents of Public Housing | - |
| Patients with Limited English Proficiency | - |
| Children Under 18 Years of Age | - |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed courses of COVID-19 oral antiviral medication received through the HRSA Health Center COVID-19 Therapeutics Program as the denominator.
